Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Dioscorea zingiberensis* (DZW), commonly known as yellow ginger, is a traditional Chinese medicinal plant being investigated for its therapeutic potential in metabolic disorders. Researchers at Fujian Provincial Hospital have specifically explored its application in the treatment of gestational diabetes mellitus (GDM). The primary active constituents are steroidal saponins, which are believed to exert their effects by activating the PI3K/Akt signaling pathway. This activation promotes the translocation of glucose transporter 4 (GLUT4) to the cell membrane, thereby enhancing glucose uptake and improving insulin sensitivity. Additionally, DZW exhibits significant anti-inflammatory properties, reducing the levels of pro-inflammatory cytokines such as TNF-α and IL-6, which are often elevated in GDM. Preclinical and clinical studies suggest that DZW can effectively regulate blood glucose levels and mitigate insulin resistance, potentially improving pregnancy outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dioscorea zingiberensis.